Replies to post #17500 on Ariad Pharmaceuticals Inc fka ARIA

[JJM760]

I asked Berger about that at a conference in NYC. He pretty much indicated the market was not juicy enough for Mrk to move forward.

[BTH]

They have some trials going on with MK-2206 (Akt) that will probably do well. Akt is somewhere along the PI3K

http://clinicaltrials.gov/ct2/show/NCT01295632

I think going forward these will probably bear some fruit - but - not before Ariad probably has a lot more data on '113 so all this will be relatively meaningless in the scope of things.

I never really liked ridaforolimus. The combo trials will be were it shows its true efficacy.